Drug class
TROP2-directed antibody–drug conjugate (ADC); topoisomerase I inhibitor payload
Mechanism of action
The antibody binds TROP2 on tumour cells and is internalised. Intracellular cleavage releases a deruxtecan-derived topoisomerase I inhibitor payload, causing DNA damage and tumour-cell death; a membrane-permeable payload can also produce bystander cytotoxicity.
General use cases
- Treatment of adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy under the US FDA Datroway indication approved 22 May 2026
- Treatment of adults with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer after prior EGFR-directed therapy and platinum-based chemotherapy under the earlier US indication; confirm current product label for biomarker and prior-treatment criteria
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
